中华妇产科杂志
中華婦產科雜誌
중화부산과잡지
CHINESE JOUNAL OF OBSTETRICS AND GYNECOLOGY
2010年
7期
506-510
,共5页
田种泽%李莎%刘茗露%朱向辉%赵瑞%岳养军%陈小华
田種澤%李莎%劉茗露%硃嚮輝%趙瑞%嶽養軍%陳小華
전충택%리사%류명로%주향휘%조서%악양군%진소화
宫颈肿瘤%放射疗法%化学栓塞,治疗性%预后
宮頸腫瘤%放射療法%化學栓塞,治療性%預後
궁경종류%방사요법%화학전새,치료성%예후
Uterine cervical neoplasms%Rediotherapy%Chemoembolization,therapeutic%Prognosis
目的 探讨子宫动脉介入化疗栓塞术联合放疗治疗宫颈癌的远期疗效.方法 回顾性分析兰州军区总医院自1999年1月1日至2009年8月31日间收治的经病理检查证实的632例Ⅱ~Ⅳa期宫颈癌患者的临床资料.其中,126例患者接受子宫动脉介入化疗栓塞术联合根治性放疗(动脉化疗+放疗组),506例患者仅接受根治性放疗(放疗组).晚期放射损伤按美国肿瘤放射治疗协作组和欧洲肿瘤治疗研究协作组(RTOG/EORTC)分级标准评价.对两组患者的预后及并发症的发生情况进行比较,并采用二项分类logistic回归法分析放疗并发症的相关危险因素.结果 (1)生存情况:所有患者总的1、2、5、8年生存率分别为94.4%、82.3%、48.8%、29.1%,其中动脉化疗+放疗组患者分别为96.0%、82.1%、37.2%、25.7%,放疗组分别为94.1%、80.8%、51.1%、31.5%,两组1、2年生存率分别比较,差异均无统计学意义(x2=0.009,P=0.993;x2=0.158,P=0.691),5、8年生存率分别比较,差异均有统计学意义(X2=11.197,P=0.001;x2=9.649,P=0.002).随访期内,动脉化疗+放疗、放疗组患者的复发转移率分别为77.0%(97/126)、73.3%(371/506),两组比较,差异无统计学意义(x2=0.705,P=0.401).(2)放疗并发症及其相关危险因素:所有患者Ⅱ级以上迟发性膀胱损伤发生率为5.5%(35/632),其中动脉化疗+放疗、放疗组分别为11.1%(14/126)、4.2%(21/506),两组比较,差异有统计学意义(x2=9.344,P=o.002).二项分类logistic回归法分析显示,子宫动脉介入化疗栓塞术是与迟发性膀胱损伤相关的危险因素(x2=6.440,OR=2.869,P=0.011).结论 子宫动脉介入化疗栓塞术联合放疗与单纯放疗比较,宫颈癌患者5、8年远期生存率明显降低,且子宫动脉介入化疗栓塞术为迟发性膀胱损伤发生的危险因素.因此,不推荐子宫动脉介入化疗栓塞术作为宫颈癌根治性放疗的常规辅助治疗措施.
目的 探討子宮動脈介入化療栓塞術聯閤放療治療宮頸癌的遠期療效.方法 迴顧性分析蘭州軍區總醫院自1999年1月1日至2009年8月31日間收治的經病理檢查證實的632例Ⅱ~Ⅳa期宮頸癌患者的臨床資料.其中,126例患者接受子宮動脈介入化療栓塞術聯閤根治性放療(動脈化療+放療組),506例患者僅接受根治性放療(放療組).晚期放射損傷按美國腫瘤放射治療協作組和歐洲腫瘤治療研究協作組(RTOG/EORTC)分級標準評價.對兩組患者的預後及併髮癥的髮生情況進行比較,併採用二項分類logistic迴歸法分析放療併髮癥的相關危險因素.結果 (1)生存情況:所有患者總的1、2、5、8年生存率分彆為94.4%、82.3%、48.8%、29.1%,其中動脈化療+放療組患者分彆為96.0%、82.1%、37.2%、25.7%,放療組分彆為94.1%、80.8%、51.1%、31.5%,兩組1、2年生存率分彆比較,差異均無統計學意義(x2=0.009,P=0.993;x2=0.158,P=0.691),5、8年生存率分彆比較,差異均有統計學意義(X2=11.197,P=0.001;x2=9.649,P=0.002).隨訪期內,動脈化療+放療、放療組患者的複髮轉移率分彆為77.0%(97/126)、73.3%(371/506),兩組比較,差異無統計學意義(x2=0.705,P=0.401).(2)放療併髮癥及其相關危險因素:所有患者Ⅱ級以上遲髮性膀胱損傷髮生率為5.5%(35/632),其中動脈化療+放療、放療組分彆為11.1%(14/126)、4.2%(21/506),兩組比較,差異有統計學意義(x2=9.344,P=o.002).二項分類logistic迴歸法分析顯示,子宮動脈介入化療栓塞術是與遲髮性膀胱損傷相關的危險因素(x2=6.440,OR=2.869,P=0.011).結論 子宮動脈介入化療栓塞術聯閤放療與單純放療比較,宮頸癌患者5、8年遠期生存率明顯降低,且子宮動脈介入化療栓塞術為遲髮性膀胱損傷髮生的危險因素.因此,不推薦子宮動脈介入化療栓塞術作為宮頸癌根治性放療的常規輔助治療措施.
목적 탐토자궁동맥개입화료전새술연합방료치료궁경암적원기료효.방법 회고성분석란주군구총의원자1999년1월1일지2009년8월31일간수치적경병리검사증실적632례Ⅱ~Ⅳa기궁경암환자적림상자료.기중,126례환자접수자궁동맥개입화료전새술연합근치성방료(동맥화료+방료조),506례환자부접수근치성방료(방료조).만기방사손상안미국종류방사치료협작조화구주종류치료연구협작조(RTOG/EORTC)분급표준평개.대량조환자적예후급병발증적발생정황진행비교,병채용이항분류logistic회귀법분석방료병발증적상관위험인소.결과 (1)생존정황:소유환자총적1、2、5、8년생존솔분별위94.4%、82.3%、48.8%、29.1%,기중동맥화료+방료조환자분별위96.0%、82.1%、37.2%、25.7%,방료조분별위94.1%、80.8%、51.1%、31.5%,량조1、2년생존솔분별비교,차이균무통계학의의(x2=0.009,P=0.993;x2=0.158,P=0.691),5、8년생존솔분별비교,차이균유통계학의의(X2=11.197,P=0.001;x2=9.649,P=0.002).수방기내,동맥화료+방료、방료조환자적복발전이솔분별위77.0%(97/126)、73.3%(371/506),량조비교,차이무통계학의의(x2=0.705,P=0.401).(2)방료병발증급기상관위험인소:소유환자Ⅱ급이상지발성방광손상발생솔위5.5%(35/632),기중동맥화료+방료、방료조분별위11.1%(14/126)、4.2%(21/506),량조비교,차이유통계학의의(x2=9.344,P=o.002).이항분류logistic회귀법분석현시,자궁동맥개입화료전새술시여지발성방광손상상관적위험인소(x2=6.440,OR=2.869,P=0.011).결론 자궁동맥개입화료전새술연합방료여단순방료비교,궁경암환자5、8년원기생존솔명현강저,차자궁동맥개입화료전새술위지발성방광손상발생적위험인소.인차,불추천자궁동맥개입화료전새술작위궁경암근치성방료적상규보조치료조시.
Objective To investigate the long-term curative effect of the radiotherapy combined uterine arterial interventional chemoembolization for cervical cancer.Methods Records of 632 patients with cervical cancer stage Ⅱ-Ⅳa proved by pathology in Lanzhou Command General Hospital from January 1st,1999 to August 31st.2009 were retrospective analysed.One hundrand and twenty-six cases of them were treated with radical radiothempy combined uterine arterial interventional chemoembolization(arterial chemoembolization+radiotherapy group).506 cases of them were treated with radical radiotherapy only (radiotherapy group);the evaluation of the late radiation injury was done,according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer(RTOG/EORTC)advanced radiation injury criteria.Prognosis and complications were compared between two groups,relative risk factors of radiothempy complications were identified by method of logistic regression.Results (1)Survival:the total survival mtes of 1-year,2-year,5-year and 8-year were 94.4%,82.3%,48.8%,29.1%,respectively.The survival rates of arterial chemoembolization+radiotherapy group were 96.0%.82.1%,37.2%,25.7%,while the survival rates of radiotherapy group were 94.1%,80.8%,51.1%,31.5%,in which there were significant differences between two groups (x2 = 0.009, P= 0.993; x2 =0. 158, P =0.691;X2 =11. 197,P=0. 001;x2 =9. 649,P =0.002). During the follow-up period, the rate of recurrence and metastasis in arterial chemoembolization + radiotherapy group were 77. 0% (97/126), while 73. 3% (371/ 506) in radiotherapy group ( x2 = 0. 705,P = 0. 401). (2) Radiotherapy complications and relative risk factors; the total incidence of tardive bladder injury higher than RTOG/EORTC stage II was 5.5% (35/632), while it was 11. l%(14/126)in arterial chemoembolization + radiotherapy group, 4.2% (21/506) in the radiotherapy group(x2 =9.344,P =0.002). The results of logistic regression showed that the uterine arterial interventional chemoembolization was relative risk factors of the tardive bladder injury ( x2 =6. 440, OR = 2. 869,P=0. 011). Conclusions Compared with the simple radiotherapy, there are a similar short-term survival rate and significant poor 5-year, 8-year survival rate in the patients treated with the uterine arterial interventional chemoembolization combined with radiotherapy, which also may be strong dangerous factor for the occurrence of tardive bladder injury. The results shown that the uterine arterial interventional chemoem bolization do not recommend to be routine adjuvant therapy for the radical radiotherapy of cervical cancer.